Investigation and pending class action against Pfizer alleging Pfizer concocted uses for the drug Neurontin and promoted off-label uses for which the drug had no effect, and for which there is no scientific basis to prescribe the drug.
Neurontin was originally sold by Parke-Davis, which was a subsidiary of Warner Lambert, which in turn was acquired by Pfizer, Inc. in 2000-2001. Through its sales of Neurontin, these companies made profits which exceeded 3 billion dollars. The manufacturer of Neurontin fraudulently marketed this drug to doctors as a treatment for the following illnesses: Bipolar Disorder; Pain Syndromes; Peripheral Neuropathy; Diabetic Neuropathy; Reflex Sympathetic Dystrophy (RSD); Attention Deficit Disorder (ADD); Restless Leg Syndrome (RLS); Trigeminal Neuralgia; Essential Tremor Periodic Limb Movement; Migraines; Drug and Alcohol Withdrawal Seizures. If you were prescribed Neurontin as a treatment for any of the above illnesses, you may be entitled to reimbursement for the costs of this medicine and other damages.
Do not change medications without first consulting your doctor.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.